search
Back to results

Long-term Clinical Effectiveness of the Delta Xtend Reverse Total Shoulder

Primary Purpose

Cuff Tear Arthropathy, Osteoarthritis With Cuff Deficiency, Rheumatoid Arthritis

Status
Terminated
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Delta Xtend Reverse Total Shoulder
Sponsored by
DePuy International
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cuff Tear Arthropathy focused on measuring total shoulder replacement, rotator cuff, osteoarthritis, rheumatoid arthritis, Delta Extend

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female subjects, aged less than 85 years inclusive.
  • Subjects who have cuff tear arthropathy, osteoarthritis with cuff deficiency, rheumatoid arthritis, post traumatic injury, or a need for revision surgery of a failed anatomic prosthesis in the left or right shoulder, which requires (total) shoulder arthroplasty.
  • Subjects with radiographic evidence of sufficient bone stock to seat and support the Delta XtendÔ Reverse Total Shoulder System.
  • Subjects who in the opinion of the Clinical Investigator are considered suitable for treatment with the Delta Xtend Reverse Total Shoulder System.
  • Patients with a life expectancy of greater than 12 months.
  • Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained.
  • Subjects who, in the opinion of the Clinical Investigator, are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.

Exclusion Criteria:

  • Male and female subjects aged 86 years or older.
  • Subjects with complete deltoid muscle palsy in the target joint as determined by clinical evaluation.
  • Subjects with active local or systemic infection or with a history of general or local infections in the target joint over the past 12 months.
  • Subjects with severe deformities, or tumours, that would impair fixation or proper positioning of the implant.
  • Subjects with no significant muscle, nerve or vascular disease.
  • Subjects with a pathology that, in the opinion of the Clinical Investigator, will adversely affect healing.
  • Known allergic reactions to implant materials (e.g. bone cement, metal, polyethylene) implant corrosion or implant wear debris.
  • Subjects with a known history of poor compliance to medical treatment.
  • Subjects who, in the opinion of the Clinical Investigator, have an existing condition that would compromise their participation and follow-up in this clinical investigation.
  • Women who are pregnant.
  • Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.
  • Subjects who have participated in a clinical investigation with an investigational product in the last month.
  • Subjects who are currently involved in any injury litigation claims.

Sites / Locations

  • Universitair Ziekenhuis
  • Clinique Generale D'Annecy
  • CHRU Reims Hôpital Maison Blanche
  • Polyclinique de l'Atlantique
  • Krankenhaus Munchen Bogenhausen

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Delta Xtend Reverse Total Shoulder

Arm Description

Orthopaedic implant for total shoulder replacement

Outcomes

Primary Outcome Measures

Postoperative functionality through a difference in Constant Score post-treatment, as compared with pre-treatment results.

Secondary Outcome Measures

Postoperative functionality at 12weeks, 1, 2, 5 and 10 years through a difference in the Constant score, ASES score, U-Penn score and EQ-5D as compared with pre-treatment scores.
Determine implant survivorship and surgical revision information at 1, 2, 5 and 10 years via Kaplan-Meier survival analysis.

Full Information

First Posted
August 15, 2008
Last Updated
April 20, 2016
Sponsor
DePuy International
search

1. Study Identification

Unique Protocol Identification Number
NCT00737087
Brief Title
Long-term Clinical Effectiveness of the Delta Xtend Reverse Total Shoulder
Official Title
A Multi-centred, Non-comparative, Non-randomised, Open, Post Marketing Investigation to Look at the Long-term Clinical Efficacy of the Delta Xtend Reverse Total Shoulder Used in the Treatment of Shoulders With Rotator Cuff Deficiencies.
Study Type
Interventional

2. Study Status

Record Verification Date
March 2016
Overall Recruitment Status
Terminated
Why Stopped
Study was stopped due to low follow-up compliance at study sites.
Study Start Date
November 2007 (undefined)
Primary Completion Date
October 2013 (Actual)
Study Completion Date
August 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
DePuy International

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This post-marketing study is designed to collect data relating to the use of the Delta Xtend™ Total Shoulder Replacement System in shoulder with rotator cuff deficiencies. This allows for continued monitoring of the performance and safety of the prosthesis in a broader range of clinical situations.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cuff Tear Arthropathy, Osteoarthritis With Cuff Deficiency, Rheumatoid Arthritis, Post Traumatic Injury to Shoulder, Revision Surgery of a Failed Anatomic Shoulder Prosthesis
Keywords
total shoulder replacement, rotator cuff, osteoarthritis, rheumatoid arthritis, Delta Extend

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
144 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Delta Xtend Reverse Total Shoulder
Arm Type
Other
Arm Description
Orthopaedic implant for total shoulder replacement
Intervention Type
Device
Intervention Name(s)
Delta Xtend Reverse Total Shoulder
Intervention Description
Orthopaedic implant for total shoulder replacement
Primary Outcome Measure Information:
Title
Postoperative functionality through a difference in Constant Score post-treatment, as compared with pre-treatment results.
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Postoperative functionality at 12weeks, 1, 2, 5 and 10 years through a difference in the Constant score, ASES score, U-Penn score and EQ-5D as compared with pre-treatment scores.
Time Frame
12weeks, 1, 2, 5 and 10 years
Title
Determine implant survivorship and surgical revision information at 1, 2, 5 and 10 years via Kaplan-Meier survival analysis.
Time Frame
1, 2, 5 and 10 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female subjects, aged less than 85 years inclusive. Subjects who have cuff tear arthropathy, osteoarthritis with cuff deficiency, rheumatoid arthritis, post traumatic injury, or a need for revision surgery of a failed anatomic prosthesis in the left or right shoulder, which requires (total) shoulder arthroplasty. Subjects with radiographic evidence of sufficient bone stock to seat and support the Delta XtendÔ Reverse Total Shoulder System. Subjects who in the opinion of the Clinical Investigator are considered suitable for treatment with the Delta Xtend Reverse Total Shoulder System. Patients with a life expectancy of greater than 12 months. Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained. Subjects who, in the opinion of the Clinical Investigator, are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups. Exclusion Criteria: Male and female subjects aged 86 years or older. Subjects with complete deltoid muscle palsy in the target joint as determined by clinical evaluation. Subjects with active local or systemic infection or with a history of general or local infections in the target joint over the past 12 months. Subjects with severe deformities, or tumours, that would impair fixation or proper positioning of the implant. Subjects with no significant muscle, nerve or vascular disease. Subjects with a pathology that, in the opinion of the Clinical Investigator, will adversely affect healing. Known allergic reactions to implant materials (e.g. bone cement, metal, polyethylene) implant corrosion or implant wear debris. Subjects with a known history of poor compliance to medical treatment. Subjects who, in the opinion of the Clinical Investigator, have an existing condition that would compromise their participation and follow-up in this clinical investigation. Women who are pregnant. Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes. Subjects who have participated in a clinical investigation with an investigational product in the last month. Subjects who are currently involved in any injury litigation claims.
Facility Information:
Facility Name
Universitair Ziekenhuis
City
Gent
ZIP/Postal Code
B-9000
Country
Belgium
Facility Name
Clinique Generale D'Annecy
City
Annecy
ZIP/Postal Code
74000
Country
France
Facility Name
CHRU Reims Hôpital Maison Blanche
City
Reims
ZIP/Postal Code
51092
Country
France
Facility Name
Polyclinique de l'Atlantique
City
St Herblain
ZIP/Postal Code
44819
Country
France
Facility Name
Krankenhaus Munchen Bogenhausen
City
Munchen
ZIP/Postal Code
81925
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

Long-term Clinical Effectiveness of the Delta Xtend Reverse Total Shoulder

We'll reach out to this number within 24 hrs